This audiobook explains what lung cancer is, its staging, different treatment and how symptoms can be controlled. It also signposts people affected by cancer to other sources of support.

Track 19 - Relationships

Track 06 - Staging lung cancer

BUFFALO, NY – June 27, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on June 17, 2025, titled “Molecular landscape of HER2-mutated non-small cell lung cancer in Northeastern Brazil: Clinical, histopathological, and genomic insights.”

In this study, researchers led by first authors Cleto Dantas Nogueira from the Federal University of Ceará and Argos Pathology Laboratory and Samuel Frota from Argos Pathology Laboratory, along with corresponding author Fabio Tavora from the previously mentioned institutions and Messejana Heart and Lung Hospital, investigated how HER2 gene mutations appear in cases of non-small cell lung cancer (NSCLC) in Northeastern Brazil. The team found that HER2 mutations showed significant genetic diversity and were often associated with other cancer-related genetic changes. These findings revealed diagnostic and treatment challenges in a population that is rarely studied, emphasizing the need for expanded access to molecular testing and targeted therapies.

HER2 mutations are a known factor in several cancers, including breast and gastric cancers. In lung cancer—particularly NSCLC—these mutations are less common but remain clinically significant. Most existing research on HER2-mutated lung cancer focuses on high-income countries, leaving important gaps in knowledge about underrepresented regions such as Latin America. This study helps fill that gap by analyzing 13 patients with HER2-mutated NSCLC using clinical, pathological, and genomic data.

The patients ranged in age from 34 to 82 years, and more than half were women. About half had never smoked. Their tumors often displayed complex genetic profiles, including additional mutations in genes such as TP53, KRAS, and STK11. The most common HER2 mutation identified was an insertion in exon 20, a known hotspot for activating mutations.

“Trastuzumab deruxtecan (T-DXd) is the first HER2-targeted agent to show clinical efficacy in HER2-mutant non-small cell lung cancer (HER2m NSCLC).”

Treatment strategies among the patients varied. Only one individual received HER2-targeted therapy. Most were treated with surgery, chemotherapy, immunotherapy, or a combination of these approaches. Outcomes also differed, with some patients surviving for years and others dying within months of diagnosis. These findings reinforce the need for early diagnosis and improved access to advanced treatments, particularly in low-resource settings.

The study emphasizes the value of comprehensive molecular profiling in NSCLC. Because HER2 mutations often occur alongside other genetic alterations, full genomic analysis is crucial for guiding treatment decisions. Yet, such testing is not always available. The researchers propose a tiered diagnostic approach, beginning with basic screening and expanding to more advanced tests when necessary, to enhance patient care.

This study provides valuable insights into the molecular characteristics of HER2-mutated NSCLC in a Brazilian population, highlighting the complexity and clinical relevance of these alterations. Larger studies are needed to clarify the prevalence and prognostic significance of HER2 mutations, as well as their impact on treatment response and survival. This knowledge is essential for advancing effective HER2-targeted therapies. The findings also support broader implementation of international clinical guidelines in Latin America and highlight the critical need to include underrepresented populations in cancer research.

DOI - https://doi.org/10.18632/oncotarget.28737

Correspondence to - Fabio Tavora - stellacpak@outlook.com

Video short - https://www.youtube.com/watch?v=hr5R9iDBFFI

To learn more about Oncotarget, please visit https://www.oncotarget.com.

MEDIA@IMPACTJOURNALS.COM

Oncotarget

HER2-Mutated NSCLC in Brazil Shows Diverse Genetic Patterns and Treatment Gaps

Summer Colling and Emma Wille speak with oncology experts Nkiru Ibeanu, Neha Anand, Anna Simmons and David Dahan about the 2025 American Society of Clinical Oncology (ASCO) conference. Deeper coverage is available through Datamonitor Healthcare

Datamonitor Healthcare Podcast: ASCO 2025

On this episode of "Let's Just Talk!" with host Kathryn Raaker:

Our first guest is Dr. Anthony “Nino” Sireci, Senior Vice President of Clinical Biomarkers, Laboratories, and Diagnostics at Eli Lilly. In recognition of World Lung Cancer Day on August 1st, Dr. Sireci discusses the vital role of biomarker testing in the early detection and personalized treatment of Non-Small Cell Lung Cancer (NSCLC), which represents the majority of lung cancer diagnoses. His insights shed light on how advancements in precision medicine are transforming patient outcomes.

Next, we welcome award-winning author and longtime mentor Jody Lynn Nye, Coordinating Judge of the L. Ron Hubbard Writers of the Future contest and editor of Volume 41 in the acclaimed anthology series. With a career spanning over four decades, Jody has authored more than 50 books and 200 short stories. She shares her experience nurturing emerging science fiction and fantasy writers, her work at Dragon Con’s writers' workshop, and her dedication to helping new voices thrive in the literary world.

WCVG 1320 AM and 103.9 FM -Sireci-Nye-7-28-2025-Lets Just Talk

On this episode of "Let's Just Talk!" with host Kathryn Raaker:

Our first guest is Dr. Anthony “Nino” Sireci, Senior Vice President of Clinical Biomarkers, Laboratories, and Diagnostics at Eli Lilly. In recognition of World Lung Cancer Day on August 1st, Dr. Sireci discusses the vital role of biomarker testing in the early detection and personalized treatment of Non-Small Cell Lung Cancer (NSCLC), which represents the majority of lung cancer diagnoses. His insights shed light on how advancements in precision medicine are transforming patient outcomes.

Next, we welcome award-winning author and longtime mentor Jody Lynn Nye, Coordinating Judge of the L. Ron Hubbard Writers of the Future contest and editor of Volume 41 in the acclaimed anthology series. With a career spanning over four decades, Jody has authored more than 50 books and 200 short stories. She shares her experience nurturing emerging science fiction and fantasy writers, her work at Dragoncon writers' workshop, and her dedication to helping new voices thrive in the literary world.



 Don’t miss this inspiring and informative episode!

Dan Perkins Media-Sireci-Nye-7-30-2025-Lets Just Talk

WELP Greenville SC 1360AM & 104.3 FM-Sireci-Nye-7-31-2025-Lets Just Talk

WNWR The Word 1540 AM Philadelphia-Sireci-Nye-8-02-2025-Lets Just Talk

KKIM-WBRI-KCLE-WSKY-WEZZ -Sireci-Nye-8-02-2025- Lets Just Talk

Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality. While the development of targeted therapies has improved outcomes for many patients with EGFR-mutated NSCLC, those with rare EGFR variants often face limited treatment options, especially when the disease involves the central nervous system (CNS).

A recent research paper, titled “Durable complete response in leptomeningeal disease of EGFR mutated non-small cell lung cancer to amivantamab, an EGFR-MET receptor bispecific antibody, after progressing on osimertinib” published in Volume 16 of Oncotarget, describes a patient with NSCLC harboring two uncommon EGFR mutations—G719A and A289V—who experienced a prolonged and clinically significant response to amivantamab monotherapy, after prior treatments had failed.

Full blog - https://www.oncotarget.org/2025/08/26/amivantamab-monotherapy-in-rare-egfr-mutated-advanced-nsclc/

Paper DOI - https://doi.org/10.18632/oncotarget.28730

Correspondence to - Young Kwang Chae - young.chae@northwestern.edu

Video short - https://www.youtube.com/watch?v=UEiCz834a8c

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28730

Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/

Keywords - cancer, amivantamab, monotherapy, rare EGFR mutation, NSCLC, leptomeningeal disease

About Oncotarget 

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

Facebook - https://www.facebook.com/Oncotarget/
X - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/@OncotargetJournal
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/
Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh

MEDIA@IMPACTJOURNALS.COM

Amivantamab Monotherapy in Rare EGFR-Mutated Advanced NSCLC

Citeline places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfect combination of news and information together with penetrating insight and analysis. Citeline is a leader in the field of healthcare industry information.

Kathryn Raaker hosts a nationally syndicated magazine format radio program on AM/FM, Internet streaming, and on her free iTunes App. The show features topics for today’s audience. Whether it is a guest talking about the newest technology, politics, health, or other topics, it is all about informing her listeners. Kathryn has been in broadcasting for almost 30 years and is featured on the Wilkins Radio Networks, Fairfax Radio Network, W4Cy & W4Vet Networks, and WVFR AM out of Pittsburg. So tune into "Let’s Just Talk! Radio" to be informed and entertained!

Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Oncotarget is now indexed by MEDLINE, PubMed and PMC/PubMed.

Read about the Oncotarget Scientific Integrity Process: https://www.oncotarget.com/scientific_integrity/

Whatever cancer throws your way, we’re right there with you to offer physical, financial and emotional support.

New tracks tagged #nsclc